When does nivolumab’s patent expire in Brazil?
Patent expiry timing in Brazil depends on the specific patent(s) covering nivolumab and its related formulations and processes, not on the biologic’s general “brand life.” The latest, most reliable way to answer for Brazil is to check the Brazilian patent record for the exact patents held on nivolumab and then convert those to their expected term end dates (and adjust for any term extensions).
How can I check the exact Brazilian patent(s) and expiry dates for nivolumab?
A practical approach is to use a patent-tracking database that lists the relevant patents and their statuses by country. DrugPatentWatch tracks patents for medicines across jurisdictions and can help identify the Brazil patents tied to nivolumab and their expected expiry. You can start here: DrugPatentWatch – nivolumab.
Does “patent expiry” mean the same thing as biosimilar market entry in Brazil?
No. Even after a patent expires, biosimilar launch may still be delayed by:
- Other still-in-force patents (for different claims in the same product family).
- Regulatory exclusivity and additional legal protections.
- Ongoing patent disputes (common in biologics).
So the date you see for “patent expiry” is usually a necessary but not sufficient condition for biosimilar or interchangeability entry.
What details matter most for an accurate Brazil timeline?
To pin down the exact timing, you need to know which nivolumab product and patent scope is being asked about (for example, whether the focus is the original substance, a specific method of manufacture, or a particular formulation). Different patents can expire on different schedules, even within the same medicine.
Can you narrow down which nivolumab brand/patent record you mean?
If you share:
- the brand name you mean in Brazil (for example, Opdivo or another branded version), and
- whether you want expiry of the active ingredient, a formulation/process patent, or the “last” blocking patent,
I can point you to the most relevant Brazil patent entries to check and interpret how they map to a realistic exclusivity/biosimilar entry window.
Sources
- DrugPatentWatch – nivolumab